SERDs (estrogen receptor degraders): all 235 studies that test it

Page 1 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsNot yet recruitingNCT07918859Phase 1
• Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaNot yet recruitingNCT07840443Phase 2
• Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingNCT07832227Phase 2
• A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentRecruitingNCT07827573Phase 3
• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingNCT07766018Phase 2
• Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot yet recruitingNCT07753954Phase 2
• Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingNCT07717450Phase 3
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingNCT07634601Phase 2
• A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2
• Elacestrant in Advanced Triple Positive Breast CancerRecruitingNCT07612215Phase 1/2
• Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingNCT07604272Phase 1
• A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)RecruitingNCT07541079Phase 3
• Ph 2 Elacestrant in ER Positive Uterine SarcomasRecruitingNCT07467772Phase 2
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingNCT07427394Phase 2
• Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingNCT07410559Phase 2
• Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingNCT07395336Phase 2
• Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07333937Phase 2
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingNCT07287098Phase 2
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruitingNCT07242352Phase 3
• A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionRecruitingNCT07231991Phase 1
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)RecruitingNCT07222215Phase 2
• A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingNCT07209449Phase 2
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingNCT07198724Phase 1/2
• Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingNCT07195227Phase 2
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingNCT07191717Phase 2
• A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1
• A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerRecruitingNCT07159451Phase 2
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruitingNCT07085767Phase 3
• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingNCT07054190Phase 2
• Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNot yet recruitingNCT07005882Phase 2
• Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female VolunteersRecruitingNCT06995482Phase 1
• Circulating Tumor DNARecruitingNCT06923527Phase 2
• Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingNCT06849947Phase 2
• Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingNCT06663072Phase 1
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingNCT06259929Phase 2
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingNCT06201234Phase 2
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingNCT06075953Phase 2
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingNCT05982093Phase 2
• Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerRecruitingNCT05816655Phase 2
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingNCT05774951Phase 3
• Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingNCT05536128Phase 2
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingNCT05524584Phase 2
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingNCT05512364Phase 3
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2
• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingNCT05305924Phase 2
• Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
• Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerRecruitingNCT04646759Phase 3
• A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
• Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingNCT04337658Phase 3
• Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerRecruitingNCT04263298Phase 3
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingNCT06206837Phase 1/2Results posted
• A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy AdultsCompletedNCT05673889Phase 1Results posted
• Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%CompletedNCT05659563Phase 2Results posted
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingNCT05654623Phase 3Results posted
• A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy AdultsCompletedNCT05652660Phase 1Results posted
• A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryCompletedNCT05549505Phase 2Results posted
• A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy AdultsCompletedNCT05538312Phase 1Results posted
• A Study of Imlunestrant (LY3484356) in Healthy WomenCompletedNCT05509816Phase 1Results posted
• A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Active, not recruitingNCT05463952Phase 1Results posted
• A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedNCT05444556Phase 1Results posted
• A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedNCT05440344Phase 1Results posted
• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
• A Study of [¹⁴C]-LY3484356 in Healthy Female ParticipantsCompletedNCT04991766Phase 1Results posted
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
• A Study of LY3484356 in Healthy Female ParticipantsCompletedNCT04840888Phase 1Results posted
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing PotentialCompletedNCT04680273Phase 1Results posted
• A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryCompletedNCT04647487Phase 1Results posted
• A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompletedNCT04588298Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingNCT04576455Phase 2Results posted
• A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerCompletedNCT04505826Phase 1/2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)CompletedNCT04436744Phase 2Results posted
• Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerTerminatedNCT04305236Phase 2Results posted
• Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing PotentialCompletedNCT04274075Phase 1Results posted
• Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyTerminatedNCT04256941Phase 2Results posted
• A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingNCT04214288Phase 2Results posted
• A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT04072952Phase 1/2Results posted
• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results posted
• A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerCompletedNCT03916744Phase 1Results posted
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3Results posted
• Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedNCT03643510Phase 2Results posted
• Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results posted
• Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast CancerCompletedNCT02953860Phase 2Results posted
• Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.TerminatedNCT02936206Phase 1Results posted
• Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus PalbociclibCompletedNCT02913430Early Phase 1Results posted
• Estrogen Receptor Antagonist in Patients With Pulmonary Arterial HypertensionCompletedNCT02911844Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor SymptomsTerminatedNCT02653417Phase 2Results posted
• A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantTerminatedNCT02540330Phase 2Results posted
• Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerCompletedNCT02491983Phase 2Results posted
• A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT02447328Phase 4Results posted
• Neoadjuvant Hormonal Therapy Combined With ChemoimmunotherapyTerminatedNCT02345772Phase 1/2Results posted
• Endocrine Response in Women With Invasive Lobular Breast CancerCompletedNCT02206984Phase 2Results posted
• Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results posted
• 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.TerminatedNCT02000596Phase 2Results posted

← SERDs (estrogen receptor degraders) overview